Assessing the effectiveness of Upadacitinib for adults with Axial Spondyloarthritis

Effectiveness of Upadacitinib in Patients With Axial Spondyloarthritis Suffering From Typical Disease Activity and Pain in a Real-World Setting

Observational AbbVie · NCT05094128

This study is testing how well Upadacitinib works for adults with axial spondyloarthritis to see if it helps reduce pain and improve their quality of life.

Quick facts

Study typeObservational
Enrollment352 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsupadacitinib, tofacitinib, baricitinib, filgotinib
Locations72 sites (Baden-Baden, Baden-Wurttemberg and 71 other locations)
Trial IDNCT05094128 on ClinicalTrials.gov

What this trial studies

This observational study evaluates the real-world effectiveness of Upadacitinib in adult participants diagnosed with axial spondyloarthritis (axSpA). It aims to assess disease activity, pain levels, and patient-reported outcomes in individuals receiving Upadacitinib as prescribed by their physicians. Approximately 352 participants will be enrolled across various locations in Germany, focusing on the impact of treatment on chronic pain and overall quality of life.

Who should consider this trial

Good fit: Ideal candidates for this study are adults diagnosed with active axial spondyloarthritis who are prescribed Upadacitinib by their physician.

Not a fit: Patients who have previously been treated with any Janus kinase (JAK) inhibitors or those with primary fibromyalgia may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the effectiveness of Upadacitinib in managing symptoms and improving the quality of life for patients with axSpA.

How similar studies have performed: While this study focuses on real-world effectiveness, similar studies evaluating Upadacitinib for other conditions have shown promising results.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinical diagnosis of axSpA upon physician's judgement.
* Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
* Upadacitinib prescribed in accordance with the local label.

Exclusion Criteria:

* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib).
* Participants with primary fibromyalgia (upon physician´s judgement)
* Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days or five half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
* Participants who cannot be treated with upadacitinib according to the applicable local label.

Where this trial is running

Baden-Baden, Baden-Wurttemberg and 71 other locations

+22 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Axial SpondylarthritisUpadacitinibRINVOQ
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.